These studies concluded that obatoclax potentiates TRAIL-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-x(L) or Mcl-1 proteins and this drug combination enhances Bid-mediated crosstalk between the mitochondrial and death receptor-mediated apoptotic pathways and may represent a novel therapeutic strategy against PC. The gene discussed is BCL2L1; the disease is pachyonychia congenita.